# A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients

> **NCT01320020** · PHASE1 · TERMINATED · sponsor: **Neovii Biotech** · enrollment: 16 (actual)

## Conditions studied

- Epithelial Cancer Patients

## Interventions

- **DRUG:** catumaxomab

## Key facts

- **NCT ID:** NCT01320020
- **Lead sponsor:** Neovii Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-02
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2013-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01320020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01320020, "A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01320020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*